Precision Therapeutics for Women's Health

Developing precision RNA therapeutics for women’s health.

Esma Bio is a preclinical-stage biotechnology company developing targeted RNA therapeutics for chronic women’s health conditions. Our lead endometriosis program aims to act within lesions, with the goal of developing a treatment that does not rely on systemic hormonal suppression.

Our programs are preclinical. Safety and efficacy have not been established in humans.

190M

estimated reproductive-age women affected worldwide

4–12 years

reported average time to diagnosis

Recurrence

symptoms can return after treatment

Source: World Health Organization, 2025. Diagnostic-delay estimates vary by setting.

The Unmet Need

Endometriosis needs more treatment options.

Endometriosis affects an estimated 190 million reproductive-age women worldwide. Persistent symptoms, delayed diagnosis, and recurrence after treatment create a substantial need for additional treatment options.

190M

estimated reproductive-age women affected worldwide

4–12 years

reported average time to diagnosis

Recurrence

symptoms can return after treatment

Source: World Health Organization, 2025. Diagnostic-delay estimates vary by setting.

Disease Burden

A substantial burden on daily life

Endometriosis can cause chronic pelvic pain and infertility and can disrupt work, education, relationships, and daily life. Symptoms and their impact vary widely between individuals.

Treatment Limitations

Effective treatments, persistent unmet needs

Medicines and surgery can provide meaningful relief, but treatment response and tolerability vary. Some hormonal treatments carry bone-density risks and limits on treatment duration. Surgery can remove lesions, yet symptoms or lesions may recur. Additional treatment options are needed.

The Esma Bio Approach

Investigating targeted RNA therapeutics for endometriosis.

Our preclinical research focuses on RNA therapeutics intended to act within endometriotic lesions. We aim to address disease-associated processes without relying on systemic hormonal suppression. Lesion selectivity, therapeutic benefit, and effects on normal tissues and endocrine function remain to be established.

Development Roadmap

Our research pipeline.

Our pipeline focuses on endometriosis, with additional discovery programs in women’s cancers and androgenetic alopecia, commonly known as pattern hair loss. All programs are preclinical.

ESB-001Endometriosis
Preclinical research
ESB-002Women’s cancers (oncology)
Discovery
ESB-003Androgenetic alopecia (pattern hair loss)
Discovery

Additional program information may be shared with prospective partners under an appropriate confidentiality agreement.

Interested in what we're building?

Get in Touch